Health Outcomes around Pregnancy and Exposure to HIV/Antiretrovirals (HOPE) study protocol: A prospective observational cohort study of reproductive-aged women living with HIV

Deborah Kacanek*, Lynn M. Yee, Tzy Jyun Yao, Jessica Lee, Ellen G. Chadwick, Paige L. Williams, Emily A. Barr, Claire A. Berman, Mariam Davtyan, Alex Diperna, Amanda Flores, Jennifer Green, Lisa B. Haddad, Laurie Hyzy, Denise L. Jacobson, Tamarra James-Todd, Jennifer Jao, Anisa Khadraoui, Kathleen M. Malee, Anna Barbara MoscickiKunjal Patel, Lisa Gaye Robinson, Liz Salomon, Kimbrae Sanders, Suzanne Siminski, Renee A. Smith, Tracy Wolbach, Kathleen M. Powis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction Over 265 000 women are living with HIV in the USA, but limited research has investigated the physical, mental and behavioural health outcomes among women living with HIV of reproductive age. Health status during the reproductive years before, during and after pregnancy affects pregnancy outcomes and long-term health. Understanding health outcomes among women living with HIV of reproductive age is of substantial public health importance, regardless of whether they experience pregnancy. The Health Outcomes around Pregnancy and Exposure to HIV/Antiretrovirals (HOPE) study is a prospective observational cohort study designed to investigate physical and mental health outcomes of young women living with HIV as they age, including HIV disease course, engagement in care, reproductive health and choices and cardiometabolic health. We describe the HOPE study design, and characteristics of the first 437 participants enrolled as of 1 January 2024. Methods and analysis The HOPE study seeks to enrol and follow 1630 women living with HIV of reproductive age, including those with perinatally-acquired HIV, at 12 clinical sites across 9 US states and Puerto Rico. HOPE studies multilevel dynamic determinants influencing physical, mental and social well-being and behaviours of women living with HIV across the reproductive life course (preconception, pregnancy, post partum, not or never-pregnant), informed by the socioecological model. Key research areas include the clinical course of HIV, relationship of HIV and antiretroviral medications to reproductive health, pregnancy outcomes and comorbidities and the influence of racism and social determinants of health. HOPE began enrolling in April 2022. Ethics and dissemination The HOPE study received approval from the Harvard Longwood Campus Institutional Review Board, the single institutional review board of record for all HOPE sites. Results will be disseminated through conference presentations, peer-reviewed journals and lay summaries.

Original languageEnglish (US)
Article numbere084835
JournalBMJ open
Volume14
Issue number7
DOIs
StatePublished - Jul 5 2024

Funding

The study was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), through award R01HD101351 to the Harvard T.H. Chan School of Public Health (Principal Investigators: PLW, EGC, DK, KMP; Protocol Co-Chairs: DK, KMP, LMY; Senior Project Manager: Natalie Lewis-Vass). The study was also supported through the Pediatric HIV/AIDS Cohort Study (PHACS) 2020 award P01HD103133.

Keywords

  • HIV & AIDS
  • Health Equity
  • MENTAL HEALTH
  • Observational Study
  • Postpartum Women
  • Pregnant Women

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Health Outcomes around Pregnancy and Exposure to HIV/Antiretrovirals (HOPE) study protocol: A prospective observational cohort study of reproductive-aged women living with HIV'. Together they form a unique fingerprint.

Cite this